1) Strategy & Leadership - Amgen's strong Q2 2026 results were driven by a diverse portfolio, demonstrating resilience against patent expirations and competition. - The company is confident in achieving durable growth through its six key growth drivers, which collectively grew at 26% YoY and accounted for nearly 70% of product sales. - Investments in innovation and technology, including AI, are central to advancing their pipeline and operational efficiency.

2) Financial & Segment Results - Total revenues exceeded $10 billion, marking a 10% increase YoY. - 22 products experienced double-digit sales growth, with 17 products annualizing over $1 billion in sales. - Key growth drivers included: - Repatha: $953 million in sales (+37% YoY) - EVENITY: $714 million in sales (+38% YoY) - TEZSPIRE: $486 million in sales (+42% YoY) - Rare Disease portfolio: $1.6 billion in sales (+21% YoY) - Innovative Oncology: Approximately $2 billion in sales (+18% YoY) - Biosimilars: $855 million in sales (+29% YoY)

3) Problems / Headwinds - Prolia and XGEVA combined sales decreased by 33% YoY to $1.1 billion due to competition from biosimilars. - The company faces challenges in maintaining market share against new entrants in the PCSK9 inhibitor space, particularly with the recent approval of Merck's oral PCSK9.

4) Operational or Product Plans - Amgen is advancing its late-stage pipeline with key products like MariTide, Olpasiran, and Xaluritamig, focusing on addressing significant unmet medical needs. - The company is expanding the indications and geographic reach of its existing products while improving dosage administration and payer access. - Investments in manufacturing capacity are set to support the launch of MariTide and other growth drivers, with capital expenditures expected to be around $2.6 billion in 2026.

5) Guidance & Outlook / Investor Angle - Amgen raised its 2026 revenue guidance to a range of $38.2 billion to $39.4 billion, and non-GAAP earnings per share guidance to $22.30 to $23.50. - The company remains committed to returning capital to shareholders, with a 6% increase in dividends to $2.52 per share. - Overall, Amgen's strategic focus on innovation, operational efficiency, and market expansion positions it well for sustained growth.

Bottom line: Amgen's robust Q2 performance, driven by strong sales across key products and strategic investments in innovation, positions the company for durable growth and increased shareholder value in the coming years.